| Dr Brian Cargill Dunbar, DO | |
|
333 Borthwick Ave, Portsmouth, NH 03801-7128 | |
| (603) 436-5110 | |
| Not Available |
| Full Name | Dr Brian Cargill Dunbar |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 23 Years |
| Location | 333 Borthwick Ave, Portsmouth, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982606042 | NPI | - | NPPES |
| 30223635 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | NH12740 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Portsmouth Regional Hospital | Portsmouth, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Portsmouth Anesthesia Associates Pa | 6002855327 | 44 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C. Debiopharm granted Novartis worldwide commercialisation rights to Debio 025 except for Japan.
Bioaxial, developers of super-resolved fluorescence microscopy for the extended imaging of live cells, today announces the completion of a EUR 1.9 million (USD 2.7 million) equity investment by three new large investors; Amorcage Technologique Investissement (a fund managed by CEA Investissement), Inserm Transfert Initiative and Viveris Management plus a range of individual investors.
A startling new case study of Chicago, led by a team of researchers at Northwestern University in Illinois, USA, suggests a 16-fold higher incidence of SARS-CoV-2 infection than previously thought. This is judging from seroprevalence (antibody presence blood testing) figures, rather than the number of RT-PCR-positives reported there (via swab sample testing of symptomatic patients).
The American Stroke Association and other organizations have spent the last decade changing the care delivery system for stroke in the United States. Now the focus must include greater emphasis on prevention and recovery, according to a special report published in Stroke: Journal of the American Heart Association.
A patient "passport," outlining individual anesthetic experiences and side effects, can help patients to better understand the procedures they have undergone in the operating room and potentially avoid future, unnecessary complications.
› Verified 6 days ago
| Entity Name | Portsmouth Anesthesia Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568584290 PECOS PAC ID: 6002855327 Enrollment ID: O20050427000080 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C. Debiopharm granted Novartis worldwide commercialisation rights to Debio 025 except for Japan.
Bioaxial, developers of super-resolved fluorescence microscopy for the extended imaging of live cells, today announces the completion of a EUR 1.9 million (USD 2.7 million) equity investment by three new large investors; Amorcage Technologique Investissement (a fund managed by CEA Investissement), Inserm Transfert Initiative and Viveris Management plus a range of individual investors.
A startling new case study of Chicago, led by a team of researchers at Northwestern University in Illinois, USA, suggests a 16-fold higher incidence of SARS-CoV-2 infection than previously thought. This is judging from seroprevalence (antibody presence blood testing) figures, rather than the number of RT-PCR-positives reported there (via swab sample testing of symptomatic patients).
The American Stroke Association and other organizations have spent the last decade changing the care delivery system for stroke in the United States. Now the focus must include greater emphasis on prevention and recovery, according to a special report published in Stroke: Journal of the American Heart Association.
A patient "passport," outlining individual anesthetic experiences and side effects, can help patients to better understand the procedures they have undergone in the operating room and potentially avoid future, unnecessary complications.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brian Cargill Dunbar, DO 383 Central Ave, Suite 323, Dover, NH 03820-6420 Ph: (603) 749-0043 | Dr Brian Cargill Dunbar, DO 333 Borthwick Ave, Portsmouth, NH 03801-7128 Ph: (603) 436-5110 |
News Archive
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C. Debiopharm granted Novartis worldwide commercialisation rights to Debio 025 except for Japan.
Bioaxial, developers of super-resolved fluorescence microscopy for the extended imaging of live cells, today announces the completion of a EUR 1.9 million (USD 2.7 million) equity investment by three new large investors; Amorcage Technologique Investissement (a fund managed by CEA Investissement), Inserm Transfert Initiative and Viveris Management plus a range of individual investors.
A startling new case study of Chicago, led by a team of researchers at Northwestern University in Illinois, USA, suggests a 16-fold higher incidence of SARS-CoV-2 infection than previously thought. This is judging from seroprevalence (antibody presence blood testing) figures, rather than the number of RT-PCR-positives reported there (via swab sample testing of symptomatic patients).
The American Stroke Association and other organizations have spent the last decade changing the care delivery system for stroke in the United States. Now the focus must include greater emphasis on prevention and recovery, according to a special report published in Stroke: Journal of the American Heart Association.
A patient "passport," outlining individual anesthetic experiences and side effects, can help patients to better understand the procedures they have undergone in the operating room and potentially avoid future, unnecessary complications.
› Verified 6 days ago
Olivera Janjic Quitkin, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 333 Borthwick Ave, Portsmouth Anesthesia Associates, Portsmouth, NH 03801 Phone: 603-436-5110 | |
Michael N Baker, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 100 Griffin Road, Suite B, Portsmouth, NH 03801 Phone: 603-431-8819 Fax: 603-427-2540 | |
Dr. Peter Chiayen Huang, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 333 Borthwick Ave, Portsmouth, NH 03801 Phone: 603-436-5110 | |
Dr. Andrew Joseph Kulesza, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 333 Borthwick Ave, Portsmouth, NH 03801 Phone: 603-436-5110 | |
Dr. Trevor B Emory, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 333 Borthwick Ave, Portsmouth, NH 03801 Phone: 603-436-5110 | |
Dr. Richard James Duffy, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 333 Borthwick Ave, Portsmouth, NH 03801 Phone: 603-436-5110 | |
Dr. Robert Lehn, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 14 Manchester Sq, Portsmouth, NH 03801 Phone: 603-766-8500 Fax: 603-766-8550 |